AN2 Therapeutics, Inc.: Easom Eric amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
AN2 Therapeutics CEO Eric Easom amended his Schedule 13G beneficial ownership filing with the SEC (accession 0001193125-26-461157), updating his reported stake in the clinical-stage biopharma company. The filing, submitted under CIK 0001193125, revises his previously disclosed passive position rather than signaling any change in control. The amendment matters because insider ownership disclosures are closely tracked by investors assessing management alignment at small-cap biotechs. Watch for the specific share count and percentage change in the amended filing, and whether further Form 4 transaction filings follow.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
AN2 Therapeutics, Inc., Easom Eric